Search

Your search keyword '"Akdis M"' showing total 843 results

Search Constraints

Start Over You searched for: Author "Akdis M" Remove constraint Author: "Akdis M"
843 results on '"Akdis M"'

Search Results

1. Human Ascaris infection is associated with higher frequencies of IL-10 producing B cells.

2. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

3. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations

4. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

5. Rhinitis associated with asthma is distinct from rhinitis alone: The <scp>ARIA‐MeDALL</scp> hypothesis

6. Rhinitis associated with asthma is distinct from rhinitis alone:The ARIA-MeDALL hypothesis

7. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

8. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

10. The ARIA-MeDALL hypothesis

11. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

13. Skin Homing T Cells

15. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

16. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

17. Climate change and global health: A call to more research and more action

18. Physical activity in asthma control and its immune modulatory effect in asthmatic preschoolers

19. Epithelial barrier hypothesis and the development of allergic and autoimmune diseases

20. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement

24. Anwendung von Biologika bei allergischen und Typ-2- entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie – ein Positionspapier von AeDA, DGAKI, GPA, ÖGAI, LGAI, ÖGP, ARIA und EAACI

25. Experimental rhinovirus infection induces an antiviral response in circulating B cells which is dysregulated in patients with asthma

26. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations

27. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

29. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

30. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

32. Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The MeDALL hypothesis

34. Developmental determinants in non-communicable chronic diseases and ageing

35. EAACI Biologicals Guidelines—Recommendations for severe asthma

36. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

37. TLR7/8 regulates type I and type III interferon signalling in rhinovirus 1b-induced allergic asthma

38. Food allergy across the globe

39. Persistent human bocavirus 1 infection and tonsillar immune responses

40. Regulated on Activation, Normal T cell Expressed and Secreted (RANTES) drives the resolution of allergic asthma

42. Global Allergy Forum and Second Davos Declaration 2013 Allergy: Barriers to cure – challenges and actions to be taken

44. Allergen-Immuntherapie in der aktuellen COVID-19-Pandemie : Ein Positionspapier von ARIA, EAACI, AeDA, GPA und DGAKI (Kurzversion)

45. EAACI Allergen Immunotherapy User's Guide

46. Efficacy and safety of treatment with dupilumab for severe asthma : A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma

47. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

48. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

49. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B<

50. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement

Catalog

Books, media, physical & digital resources